Intracellular Photocatalytic NADH/NAD(P)H Oxidation for Cancer Drug Development

Journal of the American Chemical Society, Journal Year: 2025, Volume and Issue: 147(9), P. 7161 - 7181

Published: Feb. 20, 2025

Photocatalytic cancer therapy (PCT) has emerged as a cutting-edge anticancer mechanism of action, harnessing light energy to mediate the catalytic oxidation intracellular substrates. PCT is significant current importance due its potential address limitations conventional chemotherapy, particularly drug resistance and side effects. This approach offers noninvasive, targeted treatment option by utilizing metal-based photocatalysts induce redox metabolic disorders within cells. The disrupt cell metabolism converting NADH/NAD(P)H NAD+/NAD(P)+ via photoredox processes, altering NAD+/NADH or NAD(P)+/NAD(P)H ratios, which are crucial for cellular metabolism. Ir(III), Ru(II), Re(I), Os(II) demonstrated promising efficacy. Despite these developments, gaps remain in literature translating this new into clinical trials. Perspective critically examines developments research area provides future directions designing efficient PCT.

Language: Английский

An efficient ICD inducer based on Ir(III) cyclometalated complex for anticancer and anti-migration effects towards cisplatin-resistant cancer cells

Inorganica Chimica Acta, Journal Year: 2025, Volume and Issue: unknown, P. 122601 - 122601

Published: Feb. 1, 2025

Language: Английский

Overcoming Radiation-induced PD-L1 and Cox-2 Upregulation by Nitric Oxide Gas Nanogenerator to Sensitize Radiotherapy of Lung Cancer

Biomaterials, Journal Year: 2025, Volume and Issue: unknown, P. 123335 - 123335

Published: April 1, 2025

Language: Английский